Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2020 May 29;15(5):e0233778. doi: 10.1371/journal.pone.0233778

Sevoflurane versus ketamine+diazepam anesthesia for assessing systemic and hepatic hemodynamics in rats with non-cirrhotic portal hypertension

José Ignacio Fortea 1,2,3, Marta Puerto 1,3, Carolina Fernández-Mena 1, Iris Asensio 1,3, María Arriba 4, Jorge Almagro 1, Juan Bañares 1, Cristina Ripoll 1,3,5, Rafael Bañares 1,3,6, Javier Vaquero 1,3,*
Editor: Matias A Avila7
PMCID: PMC7259621  PMID: 32469999

Abstract

The selection of the anesthetic regime is a crucial component in many experimental animal studies. In rodent models of liver disease, the combination of ketamine and diazepam (KD), generally by the intramuscular (i.m.) route, has traditionally been the anesthesia of choice for the evaluation of systemic and hepatic hemodynamics but it presents several problems. Here, we compared the performance of inhalational sevoflurane (Sevo) against the KD combination as the anesthesia used for hemodynamic studies involving the measurement of portal pressure in normal rats (Ctrl) and rats with non-cirrhotic portal hypertension induced by partial portal vein ligation (PPVL). Compared with Ctrl rats, rats with PPVL presented characteristic alterations that were not influenced by the anesthetic regime, which included liver atrophy, splenomegaly, increased plasma fibrinogen, decreased alkaline phosphatase and glycemia, and frequent ascites. The use of the KD combination presented several disadvantages compared with the inhalational anesthesia with sevoflurane, including considerable mortality, a higher need of dose adjustments to maintain an optimal depth of anesthesia, increases of heart rate, and alteration of blood biochemical parameters such as the concentration of aspartate aminotransferase, lactate, and lactic dehydrogenase. Rats anesthetized with sevoflurane, on the other hand, presented lower respiratory rates. Importantly, the anesthetic regime did not influence the measurement of portal pressure either in Ctrl or PPVL rats, with the increase of portal pressure being similar in Sevo- and KD- anesthetized groups of PPVL rats compared with their respective control groups. Overall, our results suggest that anesthesia with sevoflurane is preferable to the combination of KD for performing systemic and hepatic hemodynamic studies in rats with non-cirrhotic portal hypertension.

Introduction

Liver cirrhosis—the end-stage of chronic liver diseases—represents a significant healthcare problem with associated mortality that is similar to that of major cancers [1]. Portal hypertension—the increase of portal pressure in the portal vein territory—is responsible for most morbidity and mortality in patients with cirrhosis, constituting the leading cause of death and liver transplantation [2]. Much of our understanding of the pathophysiology of portal hypertension has been generated in experimental models in rats because they allow direct measurements of portal pressure and regional blood flows. Ketamine with or without a benzodiazepine, generally administered intramuscularly (i.m.) instead of intraperitoneally (i.p.) to avoid direct effects of anesthetics on splanchnic vessels, has been the anesthesia of choice in most studies involving measurement of portal pressure in rodents [39].

The selection of an appropriate anesthetic is a crucial component of experimental animal research not only from ethical and legal perspectives but also from a methodological point of view [10]. Indeed, inadequate control of pain and distress may interfere with experimental results due to the associated nervous and endocrine stress responses, and the anesthetic itself can also alter the animal model or the parameters that are measured [11]. The species, strain, sex, age, diet, temperature, time of day, frequency and route of administration, or the use of other drugs can also influence the effects of anesthetics [12]. Importantly, most anesthetics are metabolized in the liver, which introduces a relevant additional factor for studies of cirrhosis and portal hypertension as the effects of anesthetics may vary between experimental groups depending on the absence or presence of different degrees of liver dysfunction.

The ideal anesthetic regime for the measurement of portal pressure in experimental studies should balance several universal and disease-specific goals. Specifically, it should: 1) Be precisely titratable to ensure that animals receive adequate anesthesia without experiencing hemodynamic instability or life-threatening overdose, 2) Be compatible with available equipment and medications, 3) Have no hepatotoxicity, 4) Have minimal hepatic metabolism and elimination to limit the impact of liver disease upon its pharmacokinetics, and 5) Have no effects or minor effects on systemic and splanchnic hemodynamic parameters. None of the most used anesthetics in studies of portal hypertension in rodents, however, fulfill these criteria, including the combination of ketamine with benzodiazepines. Indeed, an unpredictable individual sensitivity to ketamine resulting in associated intra-operative mortality of up to 30% has been reported, particularly in cirrhotic rats [13]. A recent study in rats anesthetized with ketamine+xylazine undergoing diverse surgical operations (median laparotomy, bile-duct ligation, or balloon dilatation of the carotid artery) suggested that hypoxia may be a contributing factor, as oxygen supplementation reduced the mortality [14]. Studies comparing the performance of different anesthetics in the setting of cirrhosis or portal hypertension, however, are scarce and limited to relatively old studies that do not include the newer anesthetic agents [13,1519] (see Table 1 for a summary).

Table 1. Summary of studies evaluating the effects of anesthesia on hemodynamics in rats with experimental cirrhosis and/or portal hypertension.

1st author Year, Ref Species/strain/sex/BW Anesthetics doses/route of administration Main end-points PP measured Main results
Belghiti J, 1981 16 Male SD rats • Control: Awake rats Anesthetic influence on CO and PP in normal and PPVL rats. YES • PP was measured four consecutive times in normal and PPVL rats, as follows: anesthetized, awake, re-anesthetized, and re-awakened.
BW: 200–250 gr • Halothane vol % NS
• Halothane anesthesia decreased PP, MAP, and CO compared to awake rats in normal and PPVL rats.
Lee S.S, 1985 17 Male SD rats • Control: Awake rats Pentobarbital influence on hemodynamics and blood flow distribution in PPVL and sham-operated rats. YES In both Sham-operated and PPVL rats, pentobarbital anesthesia:
• Pentobarbital sodium: 5 mg/100 mg BW ip • Decreased CO and HABF, and increased TPR.
BW: NS • Did not change absolute blood flow values of splanchnic organs or PBF in either group, but the fractions of CO perfusing splanchnic organs were significantly increased in both groups.
• PP, HR, and MAP were not influenced by anesthesia in any group.
Lee S.S, 1986 18 Male SD rats • Control: Awake rats Pentobarbital influence on hemodynamics and blood flow in BDL and sham-operated rats. YES Pentobarbital anesthesia:
• Pentobarbital sodium: 5 mg/100 mg BW ip. • Decreased CO and increased TPR in both BDL and sham-operated rats.
BW: NS • Decreased PBF and HABF, and increased HR and portal resistance in BDL rats.
• Did not influence PP or MAP in BDL or sham-operated rats.
Conclusion: Pentobarbital anesthesia is not suitable for hemodynamic studies.
Debaene B, 1990 15 Male SD rats • Controls: Awake cirrhotic rats Anesthetic influence on systemic hemodynamics and splanchnic blood flow in BDL rats that were normo-or hypo-volemic. NO Before hemorrhage:
• CI was higher in conscious rats and rats receiving isoflurane.
BE: 308 ± 5 gr • Ketamine: 30 mg/kg iv bolus followed by a continuous iv infusion of 1.5 mg/kg/min • No differences in MAP, PBF, or HR between anesthetics.
• Splanchnic blood flow was lower in enflurane and similar among the rest of anesthetics; but HABF was similar in conscious rats, isoflurane and halothane groups, and lower with ketamine.
• Halothane 1% After hemorrhage:
• Enflurane 2.2% • CI and PBF decreased similarly in all groups.
• Isoflurane 1.3% • MAP was significantly higher in the ketamine and isoflurane compared with the enflurane and halothane groups. HABF was similar in conscious rats and isoflurane group.
All anesthetic agents had the same effect on PBF, but they acted differently on HABF.
Conclusion: Isoflurane seemed the most efficient anesthetic for preserving the splanchnic circulation in hypovolemic cirrhotic rats.
Sikuler E, 1991 19 Male SD rats • Controls: Awake sham and BDL rats Influence of ketamine anesthesia on systemic hemodynamics and blood flow distribution in BDL rats. NOT in awake rats. Compared with awake sham animals, anesthesia with ketamine:
• Increased PBF in sham-operated rats, but it did not change MAP, HR, CO, or HABF.
BW: 220–240 gr • Ketamine: 100–150 mg/kg im • Increased MAP in BDL rats, but it did not affect HR, CO, HABF, or PBF.
• TPR was lower in awake rats compared with anesthetized BDL and sham rats.
Van Roey G, 1997 13 Male Wistar rats • Ether. Anesthetic influence on systemic and splanchnic hemodynamics compared with the awake state in normal and cirrhotic rats that were either normo or hypovolemic. YES Hemodynamics studies in awake rats were performed 3 hours after recovery from ether narcosis for placement of catheters.
• Pentobarbital: 60 and 30 mg/kg ip for normal and cirrhotic rats.
BW: 150 gr • Ether: Dose adjusted to the depth of narcosis. Few hemodynamic effects, but continuous observation of the animal was essential.
• Ketamine: 150 and 75 mg/kg ip for normal and cirrhotic rats.
• Pentobarbital: Markedly suppressed the sympathetic nervous system and produced profound hypotension in cirrhotic rats. No influence on PP.
• Diacepam-fluanisone: 2.5–1 mg/kg ip and 2–0.6 mg/kg im for normal-cirrhotic rats. • Ketamine: Unpredictable individual sensitivity to Ketamine, especially in cirrhotic rats, with a total mortality > 30%. Ketamine did not influence MAP or PP and decreased RR in normal and cirrhotic normovolemic rats.
Cirrhosis was induced by CCl4 administration.
• Diazepam-fluanisone: Produced profound hypotension.
Conclusion: Hemodynamic experiments in cirrhotic rats should be preferably performed in awake rats.

Abbreviations: BDL: common bile duct ligation, BW: body weight, CCl4: carbon tetrachloride, CI: cardiac index, CO: cardiac output, HABF: hepatic arterial blood flow, im: intramuscular, ip: intraperitoneal, iv: intravenous, MAP: mean arterial pressure, NS: not specified, PBF: portal blood flow, PP: portal pressure, PPVL: partial portal vein ligation, RR: respiratory rate, SD: Sprague-Dawley, TPR: total peripheral resistance.

Based on the previous information, the present study aimed to compare the performance of the combination of ketamine+diazepam (KD) given i.m. versus inhalational anesthesia with sevoflurane, which has minimal (< 3%) hepatic metabolism, as the anesthetic regime for measuring hepatic and systemic hemodynamics in rats with non-cirrhotic portal hypertension induced by partial portal vein ligation (PPVL).

Materials and methods

Animals

Male Sprague-Dawley (SD) rats (310–580 g, n = 41) from Charles River Laboratories (France) were maintained in a 12:12 hour light:dark cycle with constant conditions of room temperature and air humidity. All rats always had free access to standard laboratory food and tap water. A hemodynamic study under anesthesia with inhalational sevoflurane (Sevo) or with ketamine+diazepam (KD) was performed in normal rats (Ctrl) and rats with partial portal vein ligation (PPVL). Therefore, the following four groups of rats were evaluated: Ctrl+Sevo (n = 8), Ctrl+KD (n = 11), PPVL+Sevo (n = 9), and PPVL+KD (n = 13). All studies complied with the Guide for the Care and Use of Laboratory Animals (NIH publication no. 86–23, revised 1985) and with European and local regulations. Ethical approval for the study was obtained from the Comité de Ética en Experimentación Animal of the Hospital General Universitario Gregorio Marañon and the Comunidad de Madrid (PROEX# 272/15).

Surgery

Pre-hepatic portal hypertension was induced in rats by performing a PPVL, as described by Chojkier et al. [20]. Briefly, the rats underwent a mid-laparotomy under sterile conditions and sevoflurane anesthesia. The omentum and some intestine were gently lifted out of the abdomen and covered with a gauze moistened in physiological saline. After carefully separating the hepatic artery and the portal vein proximal to the confluence of its right and left branches, a blunt-end 20-gauge needle was placed alongside the portal vein, and a 3–0 silk ligature was tightened around them. The needle was then removed, resulting in a calibrated stenosis of the portal vein. The abdominal viscera were returned into the abdomen, washed with physiological saline, and the abdomen was closed in two layers with 3–0 silk. A subcutaneous dose (0.05 mg/kg) of buprenorphine (0.3 mg/ml Buprenex vials, Reckitt Benckiser) was administered for pain relief and antiseptic ointment was applied to the surgical wound. Body temperature was monitored with a thermometer and maintained at normal levels with a warming pad throughout the operation. Once the animals recovered from the procedure, they were returned to individual cages, and physiological and behavioral signs indicative of pain or discomfort (body position, self-cleaning, body weight, motility, food intake) were assessed daily.

Anesthetic regimes for the hemodynamic studies

Hemodynamic studies with measurement of portal pressure were performed under one of the following anesthetic protocols:

  1. KD: Intramuscular injections of ketamine (75 mg/kg bw, Ketolar®, Pzifer, Madrid, Spain) and diazepam (5 mg/kg bw, Valium®, Roche, Madrid, Spain) were administered separately in the anterolateral side of each thigh. The volume of injection for each anesthetic was between 0.50–0.87 ml for ketamine and 0.33–0.58 ml for diazepam. Additional doses of ketamine (10 mg in 0.2 mL) were administered by the same route when required to maintain a sufficient depth of anesthesia. Rats anesthetized with this protocol breathed room air.

  2. Sevoflurane: The equipment for inhalational anesthesia with sevoflurane (Sevorane, Abbvie Spain SLU) consisted of a 100% oxygen tank connected to a flowmeter, a sevoflurane vaporizer (Datum Vaporizer, Blease, England), an induction chamber, and a facemask for the induction and maintenance of anesthesia during the PPVL operation and the hemodynamic study. Induction of anesthesia was performed with 5% sevoflurane in 100% O2, which was reduced to 2–3% sevoflurane for anesthesia maintenance. The percentage of sevoflurane was modified in 0.5% steps if required for adequate narcosis.

Narcosis was judged to be sufficient when animals had no pedal withdrawal reflex and did not react on cutting through the skin or the peritoneal surface. Once the surgery was initiated, the depth of anesthesia was assessed by cardiovascular parameters (heart rate and arterial pressure), breath rate, and the pedal withdrawal reflex.

Hemodynamic measurements

The hemodynamic study was performed in PPVL rats four days after the operation, as the hyperdynamic splanchnic and systemic circulation characteristic of portal hypertension are well established at this time [6]. No previous fasting was required. After anesthetizing the rats with the corresponding anesthetic regime, the right common carotid artery and external jugular vein were dissected and catheterized using a 24G Abbocath catheter (B. Braun) and a polyethylene tube (PE50, BD Intramedic), respectively, which were immediately connected to a pressure transducer. A mid-laparotomy was then performed, and part of the intestine was gently lifted out of the abdomen and covered with a gauze moistened in physiological saline. A 24G Abbocath catheter (B. Braun) was inserted into the ileocolic vein and connected to a pressure transducer to estimate the portal pressure (PP). After 5–10 minutes of stabilization, the mean arterial pressure (MAP, carotid artery), the central venous pressure (CVP, jugular vein), and the portal pressure were simultaneously registered for 10 minutes and analyzed using a multichannel PowerLab 8/35 and Lab Chart Reader software (AD Instruments). Body temperature was monitored with a rectal thermometer and always maintained at stable levels (37.0 ± 0.5 °C) with a warming pad.

At the end of the hemodynamic studies, the rats had euthanasia by exsanguination, the correct position of the portal ligature was confirmed, and the liver and spleen were dissected and weighted.

Hematological and biochemical blood laboratory tests

After finalizing the hemodynamic measurements, arterial blood from the carotid artery was collected into tubes containing EDTA or heparin. Blood cell counts were measured by an automated analyzer (BC-2800 Vet Auto Hematology Analyzer, MINDRAY Bio-Medical Electronics Co., Ltd) on EDTA-anticoagulated blood specimens. Plasma from heparinized blood was used to measure the concentration of glucose, fibrinogen, alanine (ALT) and aspartate (AST) aminotransferases, alkaline phosphatase (AP), lactic dehydrogenase (LDH), bilirubin, and albumin in an automated analyzer (ADVIA Chemistry XPT System, Siemens). Arterial blood gases were measured in a GEM Premier 3000 analyzer (Instrumentation Laboratory, Werfen).

Statistical analysis

Quantitative variables were expressed as median [interquartile range] and qualitative variables as proportions (%). Comparisons between two groups were performed using the Mann-Whitney U test. Comparisons between three or more groups were performed using One-way ANOVA with Tukey’s post-hoc tests, or the Kruskal-Wallis test with Dunn’s post-hoc tests if there was no equality of variances. Equality of variance was analyzed using the Brown-Forsythe test. Proportions were compared using Fisher’s exact test. Raw data of the experiments are provided as Supporting Information (S1 File). Statistical analyses were performed using GraphPad Prism v8 (GraphPad Software LLC, San Diego, CA).

Results

General characteristics

Rats in the PPVL groups showed the expected changes after the calibrated stenosis of the portal vein, including decreased liver-to-body weight (BW) ratio (Ctrl: 3.41% [3.16, 3.72] vs. PPVL: 2.68% [2.58, 2.93], p< 0.0001), increased spleen-to-BW ratio (Ctrl: 0.192% [0.184, 0.205] vs. PPVL: 0.265% [0.219, 0.299], p< 0.0001), and frequent development of ascites (Ctrl: 0/15 (0%) vs. PPVL: 11/21 (52.4%), p = 0.0007) (Fig 1A–1C). Ascites in PPVL rats was generally minimal (less than 1.5 ml), although one rat of each group showed higher values (8 ml and 2 ml, in the PPVL+Sevo and the PPVL+KD groups, respectively). There were no differences in any of these parameters between PPVL+Sevo and PPVL+KD groups.

Fig 1. A) Liver to body weight (BW) ratio, B) spleen to BW ratio, and C) proportion of rats presenting ascites in normal rats (Ctrl) and rats with partial portal vein ligation (PPVL) anesthetized with sevoflurane (white dots/bar portion) or ketamine+diazepam (black dots/bar portion).

Fig 1

* p< 0.05, ** p< 0.01, *** p< 0.001, p< 0.0001 ANOVA with Tukey`s post-hoc test (A), Kruskall-Wallis with Dunn’s post-hoc tests (B), or Fisher’s exact test (C). The line and dots represent the median and individual rat values, respectively.

BW loss from baseline values before the PPVL surgery to the day of the hemodynamic study was similar in PPVL+Sevo and PPVL+KD rats (-3.8% [-6.63, -0.47] vs. -5.53% [-7.36, -3.08], p = 0.35). However, all groups showed similar BW at the time of the hemodynamic study (p = 0.7, Table 2).

Table 2. Physiological, procedural and blood biochemical parameters of rats at the time of the hemodynamic study.

Ctrl+Sevo Ctrl+KD PPVL+Sevo PPVL+KD p
Body weight (g) 390 [360, 412] 393 [388, 402] 375 [341, 396] 365 [335, 421] 0.7
Duration of hemodynamic study (min) 25.3 [21.6, 27.4] 22.5 [21.0, 25.0] 21.0 [21.0, 23.5] 21.0 [21.0, 25.0] 0.15
ALT (U/l) 26 [23, 28] 35 [30, 37] 28 [22, 35] 34 [28, 50] 0.18
Bilirubin (mg/ml) 0.1 [0.1, 0.1] 0.1 [0.05, 0.1] 0.1 [0.1, 0.2] 0.1 [0.1, 0.1] 0.19
Albumin (g/dl) 3.1 [3.1, 3.4] 3.0 [2.6, 3.5] 2.7 [2.6, 3.0] 3.1 [2.5, 3.2] 0.38

Anesthesia-related mortality with the KD combination

Mortality only occurred in rats anesthetized with KD (Sevo: 0/17 (0%) vs. KD: 5/24 (20.8%), p = 0.065, Fig 2A), with rats in the Ctrl+KD group showing the highest mortality compared to the other groups (4/11 (36.4%) vs. 1/30 (3.3%), p = 0.014). All deaths occurred during the hemodynamic measurements several minutes after the cannulation of blood vessels. All dying rats presented progressive hypotension without any detectable hemorrhage, respiratory depression, or signs of inadequate depth of anesthesia.

Fig 2. A) Mortality (%) and B) proportion of rats requiring adjustment of the dose in normal rats (Ctrl, white bar portion) and rats with partial portal vein ligation (PPVL, black bar portion) anesthetized with sevoflurane (Sevo) or with ketamine+diazepam (KD).

Fig 2

Comparisons were performed with Fisher’s exact test.

Stability of depth of anesthesia and need of additional doses of anesthetics

Adequate depth of anesthesia was achieved regardless of the anesthetic choice, but the rats anesthetized with KD required more frequent dose adjustments (Sevo: 3/17 (18%) vs. KD: 12/24 (50%), p = 0.050, Fig 2B). Additional administrations of ketamine (10 mg in 0.2 ml) to maintain an optimal depth of anesthesia were required once in three rats of the Ctrl+KD group and six rats of the PPVL+KD group, and twice in three additional rats of the Ctrl+KD group. The duration of the hemodynamic study was similar in all the groups (p = 0.15, Table 2).

Influence of anesthetic regimes on cardio-respiratory parameters

The anesthetic choice had an impact on respiratory and heart rates. Specifically, rats anesthetized with KD presented an increase of heart rate and rats anesthetized with sevoflurane presented a decrease of respiratory rate with respect to the rates expected in the awake state [21] (Fig 3A and 3B). All groups showed similar MAP and CVP regardless of the type of anesthetic or the PPVL surgery (Fig 3C and 3D).

Fig 3. A) Respiratory rate, B) heart rate, C) mean arterial pressure (MAP), and D) central venous pressure (CVP) in normal rats (Ctrl) and rats with partial portal vein ligation (PPVL) anesthetized with sevoflurane (Sevo) or ketamine+diazepam (KD).

Fig 3

Median [IQR] of Ctrl+Sevo vs. Ctrl+KD vs. PPVL+Sevo vs. PPVL+KD for: Respiratory rate (brpm): 63 [57, 69] vs. 120 [100, 122] vs. 52 [45, 58] vs. 103 [93, 116]; Heart rate (bpm): 351 [334, 389] vs. 414 [371, 454] vs. 329 [316, 332] vs. 402 [374, 438]; MAP (mmHg): 81 [75, 93] vs. 88 [76, 95] vs. 84 [83, 90] vs. 96 [85, 105]; CVP (mmHg): 1.6 [1.0, 3.9] vs. -0.2 [-0.7, 0.7] vs. 1.4 [0.0, 3.1] vs. 1.5 [1.0, 3.2]. *** p< 0.001, **** p< 0.0001 One-way ANOVA with Tukey’s post-hoc tests. The line and dots represent the median and individual rat values, respectively. The dash lines represent the mean respiratory rate (142 brpm) and heart rate (340 bpm) reported in normal awake rats in prior studies [21].

The anesthetic choice did not influence the measurement of portal pressure

Compared with Ctrl animals, rats undergoing PPVL presented an increase in portal pressure (p< 0.0001) that was similar in sevoflurane- and KD-anesthetized rats (Ctrl+Sevo: 5.6 mmHg [3.9, 6.9] vs. Ctrl+KD: 5.9 mmHg [5.4, 6.4] vs. PPVL+Sevo: 13.4 mmHg [11.8, 13.7] vs. PPVL+KD: 12.6 mmHg [10.2, 13.7], p< 0.0001 PPVL groups vs. Ctrl groups, Fig 4). Importantly, there were no differences in portal pressure between sevoflurane- and KD-anesthetized Ctrl groups.

Fig 4. Portal pressure (mmHg) in normal rats (Ctrl) and rats with partial portal vein ligation (PPVL) anesthetized with sevoflurane (Sevo) or ketamine+diazepam (KD).

Fig 4

**** p< 0.0001 One-way ANOVA with Tukey’s post-hoc tests. The line and dots represent the median and individual rat values, respectively.

Anesthesia- and PPVL-related alterations in blood biochemistry

Changes in blood biochemical parameters were related to the PPVL surgery as well as to the choice of anesthetic. Compared with Ctrl rats, both sevoflurane- and KD-anesthetized PPVL rats presented elevation of fibrinogen and slight decreases of plasma glucose and alkaline phosphatase (Fig 5A–5C). Compared with rats anesthetized with sevoflurane, both Ctrl and PPVL rats anesthetized with KD presented increases of AST, lactate, and LDH (Fig 5D–5F). All groups (Ctrl+Sevo, Ctrl+KD, PPVL+Sevo, PPVL+KD) showed normal values of ALT (p = 0.18), bilirubin (p = 0.19), and albumin (p = 0.38) (Table 2).

Fig 5. A) Glucose, B) fibrinogen, C) alkaline phosphatase (AP), D) aspartate aminotransferase (AST), E) lactate, and F) lactic dehydrogenase (LDH) in normal rats (Ctrl) and rats with partial portal vein ligation (PPVL) anesthetized with sevoflurane (Sevo) or ketamine+diazepam (KD).

Fig 5

Median [IQR] of Ctrl+Sevo vs. Ctrl+KD vs. PPVL+Sevo vs. PPVL+KD for: Glucose (mg/dl): 237 [198, 297] vs. 286 [174, 403] vs. 159 [141, 182] vs. 169 [121, 207]; Fibrinogen (mg/dl): 208 [186, 232] vs. 207 [170, 226] vs. 320 [238, 375] vs. 301 [264, 403]; AP (U/l): 131 [100, 199] vs. 127 [98, 135] vs. 61 [52, 87] vs. 59 [54, 70]; AST (U/ml): 52 [44, 87] vs. 105 [98, 157] vs. 66 [49, 98] vs. 115 [102, 132]; Lactate (mmol/l): 1.9 [1.4, 2.7] vs. 4.1 [2.8, 4.9] vs. 1.8 [1.6, 2.5] vs. 4.3 [3.6, 4.6]; LDH (U/l): 243 [188, 559] vs. 582 [270, 807] vs. 167 [135, 261] vs. 434 [327, 576]. * p< 0.05, ** p< 0.01, *** p< 0.001, **** p< 0.0001 One-way ANOVA with Tukey’s post-hoc tests. The line and dots represent the median and individual rat values, respectively.

There were also differences in the arterial blood gases at the end of the hemodynamic study between sevoflurane- and KD- anesthetized rats. Thus, rats in the groups anesthetized with sevoflurane presented higher pH (7.47 [7.44, 7.48] vs. 7.39 [7.37, 7.43], p = 0.0014), partial pressure of O2 (462 mmHg [417, 483] vs. 81 mmHg [77, 89], p< 0.0001), partial pressure of CO2 (37 mmHg [34, 44] vs. 29 mmHg [24, 38], p = 0.0198), bicarbonate (26.9 mM [25.0, 28.9] vs. 19.1 mM[13.7, 24.2], p = 0.0002), and O2 saturation (100% [100, 100] vs. 96% [95, 97], p< 0.0001) compared with the groups anesthetized with KD.

Discussion

The use of anesthesia is a crucial component of research involving surgical procedures in experimental animal models, both from an ethical perspective as well as to prevent potential distress-induced interferences on parameters under study [12]. In the case of hemodynamic studies in rats with liver disease and portal hypertension, the combination of ketamine with benzodiazepines (diazepam or midazolam) has traditionally been the anesthetic regime of choice [39]. This combination, however, is not ideal, as these agents are mainly metabolized in the liver, and it associates potential cardiovascular effects and considerable mortality. The results of the present study indicate that inhalational anesthesia with sevoflurane is preferable to the combination of i.m. KD for assessing hepatic and systemic hemodynamics in rats, as sevoflurane circumvented many of the pitfalls related to the KD combination without interfering with the measurement of portal pressure.

The main observation of our study was that both KD and sevoflurane allowed a correct measurement of portal pressure and detection of portal hypertension in rats with PPVL. Although no measurement of splanchnic flow was performed, the similar increase of portal pressure in PPVL rats suggests that both anesthetic regimes had a similar effect (or no effect) on the hyperdynamic splanchnic and systemic circulation induced by the PPVL, as pre-hepatic resistance was “fixed” by the PPVL operation. Other features induced by PPVL in rats were also similar in both anesthetic groups, including the degree of liver atrophy and splenomegaly, the increase of fibrinogen or the decrease of alkaline phosphatase in plasma, a trend to lower glycemia, and the proportion of rats presenting mild ascites. Together, these observations support that the experimental model of PPVL in rats was well performed and that both anesthetic regimes were equally effective for the assessment of portal pressure in rats with non-cirrhotic portal hypertension.

Another important finding of the present study was that anesthesia with sevoflurane overcame relevant shortcomings related to the KD combination. First, sevoflurane entirely prevented anesthesia-related mortality as opposed to the 21% mortality observed in the group anesthetized with KD. Of note, KD-related mortality in our study compares favorably against other prior studies, in which up to 30–60% intra- and peri-operative mortality rates have been reported [13,14].

Second, sevoflurane allowed easier maintenance of adequate narcosis, which contrasted with the frequent need for additional doses in rats anesthetized with KD. Indeed, the unpredictable individual sensitivity to ketamine is considered the major problem with this anesthetic agent. Noteworthy, this problem is likely to be further magnified in rats with liver disease, as cytochrome P450 enzymes extensively metabolize ketamine in the liver [22]. Although its combination with diazepam improves the depth of anesthesia and prevents some undesirable effects such as muscle hypertonicity or hypersalivation, interference between ketamine and diazepam at the level of cytochrome P450 enzymes in the liver may also occur [23]. In contrast to KD, less than 5% of sevoflurane is metabolized by the liver [24], and it is a recommended anesthetic in patients with liver disease [25]. It is important to point out, however, that the PPVL model induces pre-hepatic portal hypertension, which limits the extrapolation of our findings to animal models of cirrhosis (e.g. carbon tetrachloride). Future studies would be needed to assess if the performance of the KD anesthetic regime is altered further by the potential pharmacokinetic and pharmacodynamic derangements induced by cirrhosis. Because of the pharmacokinetics and mode of administration (continuous vs. individual boluses), sevoflurane is likely to provide more stable and reproducible levels of narcosis during the registration of hemodynamic parameters than the KD combination, a possibility that was supported by the results of our study.

Third, all rats anesthetized with the KD combination presented alterations of biochemical parameters in plasma that were not present in sevoflurane-anesthetized animals. In particular, rats anesthetized with KD showed elevations of AST, lactate, and LDH, which are relevant parameters for assessing liver damage. Although our study cannot conclusively establish the exact cause of these alterations, we think that muscle cell damage secondary to the i.m. injection of KD is the most likely explanation, as the ALT was normal and the volumes needed to administer the corresponding doses of KD largely exceeded those recommended for the i.m. route (between 150% to 435% higher) [26]. Other alternatives explanations are also possible, such as the increased susceptibility to hypoxia suggested in a recent study [14]. In this regard, significant differences in arterial blood gases parameters were present between sevoflurane- and KD- anesthetized animals that survived the full study. Despite such differences, the alteration of most parameters of arterial blood gases in KD-anesthetized rats was relatively minor, and all of them presented O2 saturations above 92%, making it unlikely that hypoxia was entirely responsible for the biochemical alterations.

Finally, both control and PPVL rats anesthetized with KD presented higher heart rates than those reported in prior studies for normal awake SD rats [21]. Such an increase of heart rate by the KD combination, which has also been reported in other hemodynamic studies in SD rats [27], could affect the evaluation of cardiac output or other hemodynamic parameters and should be considered when interpreting these measurements. On the other hand, anesthesia with sevoflurane did not appear to affect heart rates, but it induced a significant decrease in the respiratory rate that was similar in control and PPVL rats. Neither sevoflurane nor the KD combination appeared to affect MAP or CVP.

Although it may be favorable from an experimental point of view, the use of sevoflurane presents some logistical disadvantages compared with the portability and minimal equipment required for the KD combination. Noteworthy, sevoflurane is expensive and requires relatively complex and bulky equipment for ensuring a correct administration to the animal as well as to prevent undesired health hazards to laboratory personnel. The increased cost of sevoflurane and its equipment, however, should be contrasted against the cost of loss of animals and failed experiments associated with the KD combination.

In conclusion, the choice of anesthetic regimes should balance practical considerations, animal welfare issues, and the potential interference with targeted research parameters. Although both sevoflurane and the KD combination allowed the appropriate measurement of portal pressure, our results indicate that sevoflurane anesthesia is a preferable option for those laboratories with access to equipment for inhalational anesthesia.

Supporting information

S1 File. Database with raw data of the experimental study.

(XLSX)

Acknowledgments

We would like to thank the personnel of the animal and surgical facilities of the Unidad de Medicina y Cirugía Experimental of the Instituto de Investigación Sanitaria Gregorio Marañón for their help with the performance of this study.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by grants from Instituto de Salud Carlos III-Fondos FEDER (PI15/01083 to JV y PI15/02037 to RB), and from Comunidad de Madrid-Fondos FEDER-FSE (Exohep-CM S2017/BMD-3727 and Nanoliver-CM Y2018/NMT-4949 to RB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Wong MCS, Huang J. The growing burden of liver cirrhosis: implications for preventive measures. Hepatol Int. 2018;12: 201–203. 10.1007/s12072-018-9865-y [DOI] [PubMed] [Google Scholar]
  • 2.Bosch J, Abraldes JG, Fernández M, García-Pagán JC. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. J Hepatol. 2010;53: 558–567. 10.1016/j.jhep.2010.03.021 [DOI] [PubMed] [Google Scholar]
  • 3.Abraldes J-G, Pasarín M, García-Pagán J-C. Animal models of portal hypertension. World J Gastroenterol. 2006;12: 6577–6584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: a primary factor for maintenance of chronic portal hypertension. Am J Physiol. 1983;244: G52–57. 10.1152/ajpgi.1983.244.1.G52 [DOI] [PubMed] [Google Scholar]
  • 5.Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology. 1984;87: 1120–1126. [PubMed] [Google Scholar]
  • 6.Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol. 1985;248: G618–625. 10.1152/ajpgi.1985.248.6.G618 [DOI] [PubMed] [Google Scholar]
  • 7.Albillos A, Colombato LA, Enriquez R, Ng OC, Sikuler E, Groszmann RJ. Sequence of morphological and hemodynamic changes of gastric microvessels in portal hypertension. Gastroenterology. 1992;102: 2066–2070. [DOI] [PubMed] [Google Scholar]
  • 8.Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology. 1992;15: 323–328. [DOI] [PubMed] [Google Scholar]
  • 9.Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol. 2005;43: 98–103. 10.1016/j.jhep.2005.02.022 [DOI] [PubMed] [Google Scholar]
  • 10.Russell WMS, Burch RL. The principles of humane experimental technique. Methuen; 1959. [Google Scholar]
  • 11.Richardson CA, Flecknell PA. Anaesthesia and post-operative analgesia following experimental surgery in laboratory rodents: are we making progress? Altern Lab Anim. 2005;33: 119–127. [DOI] [PubMed] [Google Scholar]
  • 12.Bazin J-E, Constantin J-M, Gindre G. [Laboratory animal anaesthesia: influence of anaesthetic protocols on experimental models]. Ann Fr Anesth Reanim. 2004;23: 811–818. 10.1016/j.annfar.2004.05.013 [DOI] [PubMed] [Google Scholar]
  • 13.Van Roey G, Lijnen P, Verbesselt R, Verbruggen A, Fevery J. Effect of narcotic agents and of bleeding on systemic and renal haemodynamics in healthy and CCl4-treated cirrhotic rats. Clin Sci. 1997;93: 549–556. [DOI] [PubMed] [Google Scholar]
  • 14.Mechelinck M, Kupp C, Krüger JC, Habigt MA, Helmedag MJ, Tolba RH, et al. Oxygen inhalation improves postoperative survival in ketamine-xylazine anaesthetised rats: An observational study. PLoS ONE. 2019;14: e0226430 10.1371/journal.pone.0226430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Debaene B, Goldfarb G, Braillon A, Jolis P, Lebrec D. Effects of ketamine, halothane, enflurane, and isoflurane on systemic and splanchnic hemodynamics in normovolemic and hypovolemic cirrhotic rats. Anesthesiology. 1990;73: 118–124. 10.1097/00000542-199007000-00017 [DOI] [PubMed] [Google Scholar]
  • 16.Belghiti J, Blanchet L, Lebrec D. Effects of general anaesthesia on portal venous pressure in the rat. Eur Surg Res. 1981;13: 285–289. 10.1159/000128195 [DOI] [PubMed] [Google Scholar]
  • 17.Lee SS, Girod C, Valla D, Geoffroy P, Lebrec D. Effects of pentobarbital sodium anesthesia on splanchnic hemodynamics of normal and portal-hypertensive rats. Am J Physiol. 1985;249: G528–532. 10.1152/ajpgi.1985.249.4.G528 [DOI] [PubMed] [Google Scholar]
  • 18.Lee SS, Girod C, Braillon A, Hadengue A, Lebrec D. Hemodynamic characterization of chronic bile duct-ligated rats: effect of pentobarbital sodium. Am J Physiol. 1986;251: G176–180. 10.1152/ajpgi.1986.251.2.G176 [DOI] [PubMed] [Google Scholar]
  • 19.Sikuler E, Buchs AE, Yaari A, Keynan A. Hemodynamic characterization of conscious and ketamine-anesthetized bile duct-ligated rats. Am J Physiol. 1991;260: G161–166. 10.1152/ajpgi.1991.260.1.G161 [DOI] [PubMed] [Google Scholar]
  • 20.Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol. 1981;240: G371–375. 10.1152/ajpgi.1981.240.5.G371 [DOI] [PubMed] [Google Scholar]
  • 21.Kabir MM, Beig MI, Baumert M, Trombini M, Mastorci F, Sgoifo A, et al. Respiratory pattern in awake rats: effects of motor activity and of alerting stimuli. Physiol Behav. 2010;101: 22–31. 10.1016/j.physbeh.2010.04.004 [DOI] [PubMed] [Google Scholar]
  • 22.White PF, Way WL, Trevor AJ. Ketamine—its pharmacology and therapeutic uses. Anesthesiology. 1982;56: 119–136. 10.1097/00000542-198202000-00007 [DOI] [PubMed] [Google Scholar]
  • 23.Dinis-Oliveira RJ. Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2017;2: 2–10. 10.1080/20961790.2017.1285219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Behne M, Wilke HJ, Harder S. Clinical pharmacokinetics of sevoflurane. Clin Pharmacokinet. 1999;36: 13–26. 10.2165/00003088-199936010-00002 [DOI] [PubMed] [Google Scholar]
  • 25.Starczewska MH, Mon W, Shirley P. Anaesthesia in patients with liver disease. Curr Opin Anaesthesiol. 2017;30: 392–398. 10.1097/ACO.0000000000000470 [DOI] [PubMed] [Google Scholar]
  • 26.Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci. 2011;50: 600–613. [PMC free article] [PubMed] [Google Scholar]
  • 27.Bahrami S, Benisch C, Zifko C, Jafarmadar M, Schöchl H, Redl H. Xylazine-/diazepam-ketamine and isoflurane differentially affect hemodynamics and organ injury under hemorrhagic/traumatic shock and resuscitation in rats. Shock. 2011;35: 573–578. 10.1097/SHK.0b013e318212266b [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Matias A Avila

14 Apr 2020

PONE-D-20-08262

Sevoflurane versus ketamine+diazepam anesthesia for assessing systemic and hepatic hemodynamics in rats with portal hypertension.

PLOS ONE

Dear Dr Vaquero,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by May 29 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Matias A Avila, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf and http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for including your ethics statement:  "All studies complied with the Guide for the Care and Use of Laboratory Animals (NIH publication no. 86-23, revised 1985) and with local regulations (PROEX # 272/15)."

a.) Please amend your current ethics statement to include the full name of the ethics committee that approved your specific study.

b.) Please amend your current ethics statement to confirm that your named ethics committee specifically approved this study.

For additional information about PLOS ONE submissions requirements for ethics oversight of animal work, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-animal-research  

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

3. At this time, we request that you  please report additional details in your Methods section regarding animal care, as per our editorial guidelines:  

(1) Please state the source and number of mice used in the study  

(2) Please describe the post-operative care received by the animals, including the frequency of monitoring and the criteria used to assess animal health and well-being.

Thank you for your attention to these requests.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Fortea and colleagues compared the performance of two anesthetic options in a pre-clinical model of non-cirrhotic portal hypertension, and in control animals. Authors demonstrate that ketamine+diazepam has several disadvantages including high mortality and modification of biochemical tests, which were not observed in the sevoflurane group. The topic of the study is relevant, especially considering the diverse anesthetic options and administration routes that are being used in the pre-clinical scenario. Thus, the study is interesting and, also, elegantly developed. The researchers have deep experience in the field of clinical and pre-clinical portal hypertension. I only have minor comments.

- Methods. Number of animals per group is not homogeneous. Could authors comment on the possible mortality due to PPVL procedure or other reasons leading to such variance.

- Results. Portal pressure measurement. Authors observe no differences in PP values when comparing both groups of PPVL animals. This could be predicted considering that in the PPVL model a major contributor to the increment in the porto-vascular resistance (and therefore in PP) is the physical knot that indeed modifies the pre-hepatic resistance. Splanchnic hemodynamic measurement would be interesting to further assess the effects of both anesthetics. Could authors comment here and in the manuscript?

- Results. How authors interpret their findings on sevoflurane-associated mortality? Why was it higher in the ctrl vs the ppvl group?

- Discussion. Although this is an interesting and timely study, these same analyses would be desirable in pre-clinical models of cirrhotic portal hypertension where hepatic function is compromised and, probably, hepatic metabolism of anesthetics would play a bigger role. This limitation/future opportunity should be discussed in the manuscript. Also, I would suggest to include “non-cirrhotic portal hypertension” in the title and abstract of the manuscript.

Reviewer #2: The authors have contributed with a very nice piece of work on the method of anesthesia in experiments models of non-cirrhotic portal hypertension.

the data are convincing and performed state of the art, yet I have some minor suggestions:

1. the title and through out the manuscript the authors should state that these are findings on non-cirrhotic portal hypertension. they cannot generalize those findings in cirrhotic models such as BDL and CCL4, this should be seen at first sight.

2. the data presented as text, should be presented in tables, e.g. BW, duration of the measurements, biochemistry and blood-gas-analysis.

3. in figure 1 A and B the two different groups of each sevoflurane and ketamine/diazepam should be plotted besides each other not together.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 May 29;15(5):e0233778. doi: 10.1371/journal.pone.0233778.r002

Author response to Decision Letter 0


7 May 2020

Reviewer #1:

Methods

1. Number of animals per group is not homogeneous. Could authors comment on the possible mortality due to PPVL procedure or other reasons leading to such variance.

No mortality due to the PPVL procedure was observed. The variability in the number of animals between groups was due to the increased mortality in the groups anesthetized with Ketamine-Diazepam (KD) for the hemodynamic study. In order to have similar group sizes with available hemodynamic data, we included more rats in both KD groups.

Results

2. Portal pressure measurement. Authors observe no differences in PP values when comparing both groups of PPVL animals. This could be predicted considering that in the PPVL model a major contributor to the increment in the porto-vascular resistance (and therefore in PP) is the physical knot that indeed modifies the pre-hepatic resistance. Splanchnic hemodynamic measurement would be interesting to further assess the effects of both anesthetics. Could authors comment here and in the manuscript?

We agree with Reviewer 1 that a major contributor to the increase in PP in the PPVL model is the increase in the pre-hepatic resistance caused by the physical knot. Although anesthesia cannot affect this “fixed resistance”, four days after the PPVL operation (time at which the hemodynamic study was performed) the hyperdynamic splanchnic and systemic circulation characteristic of portal hypertension are well established and contribute to the increase in PP (Sikuler et al, Am J Physiol. 1985;248: G618-625). The anesthetic regime may influence these other factors, and therefore affect PP values. Measurement of splanchnic flow as suggested by the reviewer would have provided valuable data concerning this issue.

We have added a comment in the 2nd paragraph of Discussion (page 20): “Although no measurement of splanchnic flow was performed, the similar increase of portal pressure in PPVL rats suggests that both anesthetic regimes had a similar effect (or no effect) on the hyperdynamic splanchnic and systemic circulation induced by the PPVL, as pre-hepatic resistance was “fixed” by the PPVL operation.”.

3. How authors interpret their findings on sevoflurane-associated mortality? Why was it higher in the ctrl vs the PPVL group?

No mortality was observed in control and PPVL groups anesthetized with sevoflurane. As far as the higher KD-associated mortality found in the Ctrl vs the PPVL group is concerned, we cannot provide a solid explanation. We can speculate that it may be partially related to the unpredictable individual sensitivity to ketamine, which is unlikely to be influenced by the hemodynamic changes induced by the PPVL procedure. To confirm this hypothesis, however, would likely require very large sample-size of both groups.

Discussion

4. Although this is an interesting and timely study, these same analyses would be desirable in pre-clinical models of cirrhotic portal hypertension where hepatic function is compromised and, probably, hepatic metabolism of anesthetics would play a bigger role. This limitation/future opportunity should be discussed in the manuscript. Also, I would suggest to include “non-cirrhotic portal hypertension” in the title and abstract of the manuscript.

We agree with both reviewers in this issue. This limitation has been included in the 4th paragraph of Discussion (page 21):

“It is important to point out, however, that the PPVL model induces pre-hepatic portal hypertension, which limits the extrapolation of our findings to animal models of cirrhosis (e.g. carbon tetrachloride). Future studies would be needed to assess if the performance of the KD anesthetic regime is altered further by the potential pharmacokinetic and pharmacodynamic derangements induced by cirrhosis”.

We have also included “non-cirrhotic portal hypertension” in the title, abstract and throughout the manuscript.

Reviewer #2:

1. The title and throughout the manuscript the authors should state that these are findings on non-cirrhotic portal hypertension, they cannot generalize those findings in cirrhotic models such as BDL and CCL4, this should be seen at first sight.

We agree with both reviewers in this issue. This limitation has been included in the 4th paragraph of Discussion (page 21):

“It is important to point out, however, that the PPVL model induces pre-hepatic portal hypertension, which limits the extrapolation of our findings to animal models of cirrhosis (e.g. carbon tetrachloride). Future studies would be needed to assess if the performance of the KD anesthetic regime is altered further by the potential pharmacokinetic and pharmacodynamic derangements induced by cirrhosis”.

We have also included “non-cirrhotic portal hypertension” in the title, abstract and throughout the manuscript.

2. The data presented as text, should be presented in tables, e.g. BW, duration of the measurements, biochemistry, and blood-gas-analysis.

A new Table has been added with the data of BW, duration of the hemodynamic study and blood biochemistry. as suggested by the reviewer (Table 2, page 15). We preferred to leave arterial blood gas data in the text, as we presented compounded data of the Ctrl and PPVL groups of each anesthetic group.

3. In Figure 1A and B the two different groups of each sevoflurane and Ketamine/Diazepam should be plotted besides each other not together.

Figure 1 has been modified according to these recommendations.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Matias A Avila

13 May 2020

Sevoflurane versus ketamine+diazepam anesthesia for assessing systemic and hepatic hemodynamics in rats with non-cirrhotic portal hypertension.

PONE-D-20-08262R1

Dear Dr. Vaquero,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Matias A Avila, Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Matias A Avila

19 May 2020

PONE-D-20-08262R1

Sevoflurane versus ketamine+diazepam anesthesia for assessing systemic and hepatic hemodynamics in rats with non-cirrhotic portal hypertension.

Dear Dr. Vaquero:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr Matias A Avila

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Database with raw data of the experimental study.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES